The non-effect of anti-interferon alpha-2a antibody on the response to inerferon therapy

Kanzo/Acta Hepatologica Japonica

Volumn 37, Issue 4, 1996, Pages 212-213

  Kobayashi, Masahiro ^b   Chayama, Kazuaki ^b   Arase, Yasuji ^b   Tsubota, Akihito ^b   Suzuki, Yoshiyuki ^b   Saitoh, Satoshi ^b   Koida, Isao ^b   Murashima, Naoya ^b   Ikeda, Kenji ^b   Hashimoto, Michie ^b   Koike, Hiromi ^b   Kobayashi, Mariko ^b   Kumada, Hiromitsu ^a   Tanaka, Masao ^b   Ogawa, Yuji ^b  

^a TORANOMON HOSPITAL   (Japan)

^b Sumitomo Metal Bio science Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERFERON ANTIBODY; VIRUS RNA;

ANTIBODY PRODUCTION; ARTICLE; CHRONIC HEPATITIS; HEPATITIS C; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; VIRUS DETECTION;

EID: 0029948801     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.37.208     Document Type: Article

References (16)

1. Chayama K, Arase Y, Koida I, et al: Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis type C. J Gastroenterol Hepatol 9: 128-133, 1994
2. Tsubota A, Chayama K, Ikeda K, et al: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19: 1088-1094, 1994
3. Yoshioka K, Kakumu S, Wakita T, et al Detection of hepatitis C virus by polymerase chain reaction and response to interferon α therapy: Relationship to genotype of hepatitis C virus. Hepatology 16: 293-299, 1992
4. Davis GL, Balart LA, Schiff, et al: Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 321: 1501-1506, 1989
5. Di Bisceglie AM, Martin F, Kassianides, et al Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 321: 1506-1511, 1989
6. Milella M, Antonelli G, Santantonio, et al Neutralizing antibodies to recombinant alpha interferon and response to therapy in chronic hepatitis C virus infection. Liver 13: 146-150, 1993
7. Bonetti P, Diodati G, Drago C, et al: Interferon antibodies in patient with chronic hepatitis C virus infection treated with rocombinant interferon alpha-2a. J Hepatol 20: 116-420, 1994
8. Urdea MS, Horn T, Fultz TJ, et al: Branched chain DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Research 24: 197-200, 1991
9. Chayama K, Tsubota A, Arase Y, et al: Quantitive analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction. J Gastroenterol Hepatol 8: 40-44, 1993
10. Tsukiyama-Kohara K, Yamaguchi K, Maki N, et al: Antigenecities of group 1 and 2 hepatitis C virus polypeptides-molecular basis of diagnosis. Virology 192: 430-437, 1993
11. Steis RG, Smith JW, Urba WJ, et al: Resistance to inteferou alpfa-2a in hairly-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318 : 1409-1413, 1988
12. Antonelli G, Currenti M, Turriziani O, Dianzani F: Neutralizing antibodies to interferon-α: Relative frequency in patient tereated with different interferon preparations. J Infect Dis 163: 882-885, 1991
13. Itri LM, Campion M, Dennin RA, et al: Incidence and clinical significance of neutralizing antibodies in patient receiving reombinant interferon alfa-2a by intramuscular injection. Cancer 59: 558-674, 1987
14. Inglada L, Porres JC, La Banda F, et al: Anti-IFN-α-titers duaring interferon therapy. Lancet ii: 1521, 1987
15. Wussow PV, Freud M, Block B, et al: Clinical significance of anti IFN-α antibody titers during interferon therapy. Lancet 2: 635-636, 1987